MiNK Therapeutics, Inc. INKT 深 沪
等待开盘 07-07 09:30:00 美东时间
11.56
-0.110
-0.94%
华盛通- 最 高11.97
- 今 开11.55
- 成交量 9015股
- 最 低 11.42
- 昨 收 11.67
- 总市值 5759.08万
- 52周最高 52.50
- 市盈率 静 --
- 换手率 0.18%
- 52周最低 8.4801
- 委 比 -98.73%
- 总股本 498.19万
- 历史最高 221.55
- 量 比 0.56
- 振 幅 4.71%
- 历史最低 4.632
- 每 手 1
- 风险率 4.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MiNK Therapeutics Announces First Patient Dosed In Randomized Phase 2 Clinical Trial Evaluating Agent-797 With SOC Vs Placebo With SOC In Patients With Severe Acute Lung Injury And Critical Illness
First patient dosed marks rapid transition from trial activation to active treatment in patients with acute lung injury from all cause pneumonia meeting Global ARDS criteriaLandmark advances a first-in-class immune
05-28 21:07
MiNK Therapeutics Presents New Clinical, Translational Data On Agent-797 Showing Pathogen Suppression, Lung Immune Restoration And Tissue Repair Activation, Supporting Ongoing Phase 2 Trial, At ATS 2026
MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases
05-20 23:10
美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
05-19 10:55
Transcript: MiNK Therapeutics Q1 2026 Earnings Conference Call
MiNK Therapeutics (NASDAQ:INKT) held its first-quarter earnings conference call...
05-15 21:46
MiNK Therapeutics Q1 EPS $(0.57) Beats $(0.78) Estimate
MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.78) by 26.92 percent. This is a 18.57 percent increase over losses of $(0.70) per share from
05-15 19:36
Earnings Scheduled For May 15, 2026
Companies Reporting Before The Bell • Traws Pharma (NASDAQ:TRAW) is expected to...
05-15 19:11
MiNK Therapeutics Presents Data Showing Agent-797, Off-The-Shelf, Allogeneic iNKT Cell Therapy Produces Fundamentally Different, Disease-Appropriate Immune Responses At ASGCT 2026
iNKT therapy, agenT-797, delivers context-dependent immune reprogramming showing activation in cancer and anti-inflammatory benefit in ARDS — from the same manufacturing donor batch, without genetic engineeringFindings
05-12 19:39
MiNK Therapeutics Presents Data From Investigator-Initiated Phase II Trial, Evaluating agenT-797, MiNK's allo-iNKT Cell Therapy, In Combination With BOT And BAL, Ramucirumab And Paclitaxel In PD-1 Refractory Gastroesophageal Cancer, At 2026 AACR Annual Meeting
First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients and long-term survival beyond 20 months in a subset of patientsInduction
04-18 03:03
